A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy
This study has been completed.
Sponsor:
St. Justine's Hospital
Collaborator:
Graceway Pharmaceuticals, LLC
Information provided by:
St. Justine's Hospital
ClinicalTrials.gov Identifier:
NCT00601016
First received: January 14, 2008
Last updated: January 24, 2008
Last verified: January 2008
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
Hemangiomas of infancy, the most common benign tumors of infancy, are congenital or early infancy lesions characterized by a rapid postnatal growth, with high expression of angiogenic stimulators for 9-18 months, followed by slow regression for 5-9 years. Current therapies for the hemangiomas are usually restricted to more severe forms due to the risks of adverse effects, inconvenience and cost. Nevertheless, a substantial amount of the psychological discomfort and morbidity can be caused by untreated hemangiomas, especially those in the face.
Recently, Imiquimod 5% cream has emerged as a safe an effective drug for several skin conditions that benefit from modulation of the activity of the immune system, such as common warts and various forms of the skin pre-cancerous and cancerous lesions. Small case reports series have suggest that it could also be useful in hemangiomas, possibly through the inhibition of the angiogenesis by local IFN production.This is a small, open label study of 16 patients to document the efficacy of the Imiquimod 5% cream in the treatment of hemangioma of infancy (primary outcome). IFN and plasma drug levels, as well as clinical examinations and blood studies, will be carried out to evaluate safety of the treatment (secondary outcome). bFGF and VEGF will be measured in blood and urine in order to study the diagnostic and predictive value of these pro-angiogenic factors in the response of hemangiomas to the treatment with Imiquimod (secondary outcome).
The study is a phase II clinical trial of a once a day application of Imiquimod 5% cream, 3 to 7 times per week for a maximum of four months. The study held at the Dermatology Clinic of Sainte-Justine Hospital, and was completed within a 20 months timeframe after IRB approval.
| Condition | Intervention | Phase |
|---|---|---|
|
Hemangioma, Capillary |
Drug: Imiquimod 5% cream |
Phase 2 |
| Study Type: | Interventional |
| Study Design: | Endpoint Classification: Safety/Efficacy Study Intervention Model: Single Group Assignment Masking: Open Label Primary Purpose: Treatment |
| Official Title: | A Phase II Study of Imiquimod 5 % Cream for the Treatment of Hemangioma in Infancy |
Resource links provided by NLM:
Further study details as provided by St. Justine's Hospital:
Primary Outcome Measures:
- To document the efficacy of Imiquimod 5% cream in the treatment of hemangioma of infancy. [ Time Frame: Cream is applied for 4 months. Visits occured at month 1, 2, 4, and 8. ] [ Designated as safety issue: No ]
Secondary Outcome Measures:
- IFN and plasma drug levels, as well as clinical examinations and blood studies, will be carried out to evaluate safety of the treatment. [ Time Frame: 4 months of treatment. Doage done at each study visits (Month 1, 2 .4 and 8). ] [ Designated as safety issue: Yes ]
- bFGF and VEGF will be measured in blood and urine in order to study the diagnostic and predictive value of these pro-angiogenic factors in the response of hemangiomas to the treatment with Imiquimod. [ Time Frame: 4 months of treament with a follow-up at 8 months. ] [ Designated as safety issue: No ]
| Enrollment: | 18 |
| Study Start Date: | March 2005 |
| Study Completion Date: | September 2006 |
| Primary Completion Date: | September 2006 (Final data collection date for primary outcome measure) |
Intervention Details:
-
Drug: Imiquimod 5% cream
- Imiquimod 5% cream = Aldara
- Item ID = GH-6203-0328-5, CUP-051119552409
- DIN number = 02239505
- Lot number -= GFK026A
Imiquimod 5% cream applied topical on hemangioma once a day , 3 to 7 times a week for a maximum of 4 months.
Other Names:
Eligibility| Ages Eligible for Study: | 2 Months to 12 Months |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- Healthy infants aged 2-12 months.
- Superficial or mixed hemangiomas in proliferative phase (growing in size in the last 1-2 months).
- Hemangiomas must be less than 10X10 cm and must not be ulcerated.
Exclusion Criteria:
- Preterm infant (less than 36 weeks of gestation).
- Ulceration of hemangioma prior to treatment.
- Immunosuppression.
- Hemangioma located on the eyelid or perianal region.
- Prior treatment of the hemangioma.
- Concomitant diseases.
- Presence of multiple hemangiomas and/or hemangiomas that would require systemic drug treatment.
- Potential difficulties with follow-up (patient from another town,difficult access to the hospital , etc.).
- History of allergy to any of the components of the drug preparation.
- Hemangiomas more than 10X 10 cm or ulcerated before the start of the treatment.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00601016
Locations
| Canada, Quebec | |
| Sainte-Justine Hospital University Center (CHU) | |
| Montreal, Quebec, Canada, H3T 1C5 | |
Sponsors and Collaborators
St. Justine's Hospital
Graceway Pharmaceuticals, LLC
Investigators
| Principal Investigator: | Catherine McCuaig, M.D. | St. Justine's Hospital |
More Information
Publications:
Bruckner, A.L. and I.J. Frieden, Hemangiomas of infancy. J Am Acad Dermatol, 2003. 48(4): p. 477-93; quiz 494-6. 2. Dinehart, S.M., J. Kincannon, and R. Geronemus, Hemangiomas: evaluation and treatment. Dermatol Surg, 2001. 27(5): p. 475-85. 3. Jacobs, A.H. and R.G. Walton, The incidence of birthmarks in the neonate. Pediatrics, 1976. 58(2): p. 218-22. 4. Margileth, A.M. and M. Museles, Cutaneous hemangiomas in children. Diagnosis and conservative management. Jama, 1965. 194(5): p. 523-6. 5. Powell, T.G., et al., Epidemiology of strawberry haemangioma in low birthweight infants. Br J Dermatol, 1987. 116(5): p. 635-41. 6. Burton, B.K., et al., An increased incidence of haemangiomas in infants born following chorionic villus sampling (CVS). Prenat Diagn, 1995. 15(3): p. 209-14. 7. Martinez, M.I., et al., Infantile hemangioma: clinical resolution with 5% imiquimod cream. Arch Dermatol, 2002. 138(7): p. 881-4; discussion 884. 8. Gampper, T.J. and R.F. Morgan, Vascular anomalies: hemangiomas. Plast Reconstr Surg, 2002. 110(2): p. 572-85; quiz 586; discussion 587-8. 9. Ceisler, E.J., L. Santos, and F. Blei, Periocular hemangiomas: what every physician should know. Pediatr Dermatol, 2004. 21(1): p. 1-9. 10. Dadras, S.S., et al., Infantile hemangiomas are arrested in an early developmental vascular differentiation state. Mod Pathol, 2004. 17(9): p. 1068-79. 11. Oliver, G. and M. Detmar, The rediscovery of the lymphatic system: old and new insights into the development and biological function of the lymphatic vasculature. Genes Dev, 2002. 16(7): p. 773-83. 12. Vikkula, M., et al., Molecular basis of vascular anomalies. Trends Cardiovasc Med, 1998. 8(7): p. 281-92. 13. Cohen, M.M., Jr., Vasculogenesis, angiogenesis, hemangiomas, and vascular malformations. Am J Med Genet, 2002. 108(4): p. 265-74. 14. Chang, J., et al., Proliferative hemangiomas: analysis of cytokine gene expression and angiogenesis. Plast Reconstr Surg, 1999. 103(1): p. 1-9; discussion 10. 15. Takahashi, K., et al., Cellular markers that distinguish the phases of hemangioma during infancy and childhood. J Clin Invest, 1994. 93(6): p. 2357-64. 16. Bielenberg, D.R., et al., Progressive growth of infantile cutaneous hemangiomas is directly correlated with hyperplasia and angiogenesis of adjacent epidermis and inversely correlated with expression of the endogenous angiogenesis inhibitor, IFN-beta. Int J Oncol, 1999. 14(3): p. 401-8. 17. Ritter, M.R., et al., Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis. Proc Natl Acad Sci U S A, 2002. 99(11): p. 7455-60. 18. Isik, F.F., et al., Monocyte chemoattractant protein-1 mRNA expression in hemangiomas and vascular malformations. J Surg Res, 1996. 61(1): p. 71-6. 19. Dosquet, C., et al., [Importance of bFGF (
Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
| Responsible Party: | Catherine McCuaig, Pricipal Investigator, CHU Siante-Justine, CHU Sainte-Justine |
| ClinicalTrials.gov Identifier: | NCT00601016 History of Changes |
| Other Study ID Numbers: | 1-Mccuaig, 1 |
| Study First Received: | January 14, 2008 |
| Last Updated: | January 24, 2008 |
| Health Authority: | Canada: Health Canada |
Keywords provided by St. Justine's Hospital:
|
Infantile hemangioma Hemangioma Hemangioma of Infancy |
benign tumors of infancy Congenital hemangioma Capillary |
Additional relevant MeSH terms:
|
Hemangioma Hemangioma, Capillary Neoplasms, Vascular Tissue Neoplasms by Histologic Type Neoplasms Imiquimod Adjuvants, Immunologic |
Immunologic Factors Physiological Effects of Drugs Pharmacologic Actions Antineoplastic Agents Therapeutic Uses Interferon Inducers |
ClinicalTrials.gov processed this record on May 23, 2013